Fujifilm Corporation will invest approximately 100 billion Yen ($935 million) in the Denmark site of Fujifilm Diosynth Biotechnologies, its CDMO for biologics and advanced therapies, to double the site’s current drug-substance manufacturing capacity and expand its capabilities to include fill–finish and enhance its current assembly, labeling and packaging services.

The investment will expand production lines for bulk drug substances with the addition of six mammalian-cell bioreactors, which would bring the total to 12 x 20,000-liter bioreactors by the fall of 2023. The development will also include the addition of the Denmark site’s first fill–finish production line (to be added by the summer of 2023) capable of producing 35 million units per annum for large-scale production. In spring 2022, a new packaging line, equipped with facilities to assemble multiple types of auto-injectors as well as automatic labeling, will be added.

In August 2019, Fujifilm invested approximately 98 billion Yen ($919 million) to acquire the Denmark site from Biogen’s manufacturing subsidiary in Denmark, for its cGMP capabilities.

The advanced capabilities at the Denmark site has led to collaborations including the recent announcement of future manufacturing capacity reservation by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.

Source: Fujifilm Corporation